Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|22|3943-3951

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.22, 2013-11, pp. : 3943-3951

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 271-273

Karger

Access to resources Recommend Favorite

Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy Is Well Tolerated and Safe in High-Risk Early Breast Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 446-453

Karger

Access to resources Recommend Favorite

Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer

By  

Oncology, Vol. 69, Iss. 5, 2005-12 ,pp. : 372-383

Karger

Access to resources Recommend Favorite

Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial

By  

Oncology Research and Treatment, Vol. 32, Iss. 8-9, 2009-07 ,pp. : 468-472

Karger

Access to resources Recommend Favorite

Sequential Administration of Doxorubicin and Paclitaxel Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil Combination (CMF) in Women with Metastatic Breast Cancer

By  

Oncology, Vol. 55, Iss. 6, 1998-10 ,pp. : 533-537

Karger

Access to resources Recommend Favorite